Pharmaceutical Product Development

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pharmaceutical Product Development, LLC.
Private
Industry Contract research organizations
Pharmaceutical
Biotechnology
Founded 1985
Key people
See Principal Officers page of the PPD Website[1]
Products Contract clinical research for pharmaceutical, biotechnology, medical device, academic and government organizations; services include discovery, development, lifecycle management and laboratory services.
Number of employees
13,000 (2014)
Website www.ppdi.com

Pharmaceutical Product Development, LLC (PPD) is a global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. The company’s clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. PPD is mainly known for conducting drug development for its clients, it also invests in developing new products through its compound partnering program.

History[edit]

PPD was founded by Fred Eshelman, Pharm.D., as a one-person consulting firm in 1985. The following year he expanded the company's scope to include development services and relocated operations from Maryland to North Carolina.

  • July 1985: Fred Eshelman, Pharm.D., founds PPD as a one-person consulting firm based in his home in Maryland.
  • 1986: Eshelman expands the company and relocates operations to Wilmington, North Carolina.
  • Jan. 1989: The company incorporates in North Carolina.
  • Jan. 1996: PPD issues its initial public stock offering and begins trading on the Nasdaq National Market System under the symbol PPDI.
  • Oct. 2005: PPD’s board of directors adopts an annual cash dividend policy.
  • July 2009: The company promotes Eshelman to executive chairman and names David Grange chief executive officer.
  • Jan. 2010: The company commemorates the 25th anniversary of its founding.
  • June 2010: PPD spins off its compound partnering division as a new and independent publicly traded company, Furiex Pharmaceuticals.
  • May 2011: David Grange retires as chief executive officer of PPD. [2]
  • Sept. 2011: PPD’s board of directors names Raymond Hill as PPD’s new chief executive officer.
  • Dec. 2011: The company is acquired by affiliates of The Carlyle Group and affiliates of Hellman & Friedman in an all-cash transaction valued at approximately $3.9 billion. [3]
  • May 2012: PPD’s board of directors names David Simmons as chairman and CEO.[4]

Location[edit]

PPD maintains its worldwide headquarters in Wilmington, N.C. The company has approximately 13,000 employees and offices in 46 countries.

Operations[edit]

PPD provides drug discovery, development, lifecycle management and laboratory services. PPD has a 300-bed healthy volunteer (Phase I) clinic and a dental research clinic in Austin, Texas.

Clinical Development Services[edit]

PPD provides product development and post-approval services for biopharmaceuticals and devices, as well as full service Phase II-IIIb clinical studies for multinational regulatory submissions. PPD also offers clinical data management and information solutions, including consulting and proprietary software tools to speed collection, analysis and reporting of clinical trial data.

Laboratory Services[edit]

PPD provides bioanalytical, cGMP product analysis, central laboratory, and vaccines and biologics lab services.

Discovery Sciences/Compound Partnering[edit]

The discovery sciences segment offers biomarker discovery services, nonclinical development and preclinical services. Through its compound partnering program, it also seeks to in-license early-stage compounds, take them through proof of concept, and out-license them to its partners for late clinical testing and commercialization. PPD shares in the risks and rewards of bringing a drug to market, gaining revenues generated by licensing fees, milestone payments and commercial royalties.

The company’s post-approval services include epidemiology, risk management and outcomes research; late-stage trials; medical information; product safety; registries and observational studies.

References[edit]

  1. ^ "Principal Officers". Retrieved 2 March 2015. 
  2. ^ William Faulkner (May 20, 2011). "David Grange retires as CEO of PPD". Wilmington StarNews. 
  3. ^ Peter Lattman (October 3, 2011). "Buyout Firms to Buy Drug Research Company for $3.9 Billion". New York Times. 
  4. ^ William Faulkner (May 23, 2012). "PPD names new CEO". Wilmington StarNews. 

External links[edit]